Αποτελέσματα Αναζήτησης
19 Μαρ 2024 · Therapeutic Interventions in Heart Failure with Preserved Ejection Fraction. The goals of therapy for HFpEF are to reduce symptoms, improve quality of life, prevent disease progression, reduce hospitalizations, and effectively manage underlying comorbidities.
5 Ιουλ 2016 · This reduces soluble guanylate cyclase (sGC) activity, cyclic guanosine monophosphate (cGMP) content, and the favorable effects of protein kinase G (PKG) on cardiomyocyte stiffness and hypertrophy. HFpEF indicates heart failure with preserved ejection fraction.
18 Σεπ 2024 · General management – For patients with heart failure with preserved ejection fraction (HFpEF), the goals of treatment are to reduce HF symptoms, increase functional status, and reduce the risk of hospital admission.
13 Απρ 2019 · Introduction. Heart failure with preserved ejection fraction (HFpEF) poses a growing burden to the healthcare system with rising prevalence paired with substantial morbidity and mortality [1, 2].
The TOPCAT (Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonist Trial) trial of spironolactone in HFpEF failed to show a reduction in the primary composite endpoint of HF hospitalization or cardiovascular death, 136 but there was substantial geographic heterogeneity, and, in the Americas, spironolactone use was ...
27 Ιαν 2022 · In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities.
16 Μαρ 2024 · The ongoing SPIRIT-HF (Spironolactone in the Treatment of Heart Failure; NCT04727073) and SPIRRIT (Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction; NCT02901184) trials will shed more light on the role of spironolactone in HFpEF.
